By Keith Gillogly
Published October 20, 2026
Bacteria are constantly secreting various molecules to compete with one another or infect a host’s cells. Yet bacteria themselves are the source of some of our most successful medicines.
“Penicillin, vancomycin, tetracycline — with all of these antibiotics, it wasn’t some clever medicinal chemist who discovered them, it was nature,” says Andrew M. Gulick, PhD, professor of structural biology in the Jacobs School of Medicine and Biomedical Sciences.
Gulick has long studied how bacteria make these chemical products and how they might be harnessed to develop new therapies. To continue this work, he recently received a new $2.2 million, five-year grant from the National Institute of General Medical Sciences, part of the National Institutes of Health (NIH).
The grant is an R35 award, a funding mechanism that the NIH says is designed to enhance scientific productivity and the chance for achieving breakthroughs by supporting a lab’s ongoing body of work rather than a specific project. The title of Gulick’s research grant is “Using the Structures of Natural Product Biosynthetic Enzymes to Guide the Discovery of Novel Molecules.”
Gulick and his lab team, including research scientist Ketan Patel, PhD, study nonribosomal peptide synthetases, or NRPSs, a family of bacterial enzymes that make peptides without using the ribosome, a cell’s typical protein builder. Peptides are short chains of amino acids that influence many biological processes.
NRPSs function like a factory, combining amino acids to create peptides and shuttling the molecule along an assembly line to different domains, which act like molecular workstations that each perform a specific chemical task.
Gulick and his colleagues have spent a decade and a half figuring out this assembly line choreography. Now, they’re focused on understanding what happens within these domains.
“It’s within the individual domains that do the unusual chemistry that we don’t have a very good handle on,” he says.
He’s particularly interested in the domains that make beta-lactams, the specific chemical structure that disrupts bacterial cell walls and a key component of many widely used antibiotics.
Using X-ray crystallography, Gulick, who’s also director of graduate studies in the Department of Structural Biology, can create atomic-scale 3D maps of these domains. By zooming in on the active sites controlling beta-lactam formation, they can identify the specific structural features and amino acids that form the active site.
After identifying an active site’s most important structural features, the researchers can determine the specific bacterial DNA sequences that encode these sites. This target DNA sequence can then be compared against a massive database of bacterial genomes.
Bacteria from the body, the soil — everywhere — have had their genomes sequenced. If any of these bacteria contain a DNA pattern that matches the critical biosynthetic sequence, it may be possible to harness their DNA to identify enzymes with the same structural features that produce similar, as yet undiscovered antibiotic molecules, Gulick explains.
“By identifying the specific structural features that allow that enzyme to make new, relevant molecules that we’re interested in, we can then look at all these sequencing databases and say, ‘oh, there’s another one here in this organism from the soil,’” Gulick says.
Gulick can then isolate the enzymes in test tubes and introduce various chemical building blocks, or substrates, to see if the enzymes produce the target molecule. From there, bacteria can be introduced to see if the novel molecules successfully kill them.
The researchers can also alter the amino acids of an enzyme’s active site to create modified versions of natural antibiotic molecules with different properties, he says.
Gulick cautions that his goal isn’t to develop new drugs and therapies right now; there’s more to discover, more to understand, first.
“We’ve been studying these enzymes for years, trying to explain how they work,” Gulick says. “As basic scientists, we want to understand the systems and the process, and there will always be more to learn.”